Theravance BioPharma(TBPH.US)

Last Updated 19:00:00 ET
longbridge loading

Theravance: Hold Rating Reiterated as Restructuring Progress and Cash Flow Visibility Support Unchanged $15 Price Target

Tip Ranks·
US
TBPH
-1.27%
US
IHE
+1.29%
US
IXJ
+0.67%
Tip Ranks·
US
TBPH
-1.27%
US
IHE
+1.29%
US
IXJ
+0.67%

Theravance BioPharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 17.7 M

Earnings Watch·
US
TBPH
-1.27%
Earnings Watch·
US
TBPH
-1.27%

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update | TBPH Stock News

StockTitan·
US
TBPH
-1.27%
StockTitan·
US
TBPH
-1.27%

Theravance Biopharma Reaches Analyst Target Price

nasdaq·
US
TBPH
-1.27%
nasdaq·
US
TBPH
-1.27%

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Moderate Buy" by Brokerages

Market Beat·
US
TBPH
-1.27%
Market Beat·
US
TBPH
-1.27%

Bora Biologics Successfully Completes 2,000L Engineering and Scale-Up Run in San Diego, Reinforcing Commercial-Scale Readiness

MorningStar·
US
TBPH
-1.27%
US
IXJ
+0.67%
US
BBH
+0.64%
MorningStar·
US
TBPH
-1.27%
US
IXJ
+0.67%
US
BBH
+0.64%

TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm

MorningStar·
US
TBPH
-1.27%
MorningStar·
US
TBPH
-1.27%

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Moderate Buy" from Analysts

Market Beat·
US
TBPH
-1.27%
Market Beat·
US
TBPH
-1.27%

Theravance Secures Long-Term YUPELRI Patent Litigation Settlement

Tip Ranks·
US
TBPH
-1.27%
Tip Ranks·
US
TBPH
-1.27%
© 2026 Longbridge｜Disclaimer